常规抗结核药物联合中药口服加超声波导入治疗浸润型淋巴结核临床观察  

Clinical observation on the treatment of infiltrating lymphatic tuberculosis with conventional antituberculosis drugs combined with oral Chinese medicine and ultrasonic induction

作　　者：王国卫[1] 梁亚充 韩朝[1] 李翠乔 霍炳杰[2] WANG Guo-wei;LIANG Ya-chong;HAN Zhao;LI Cui-qiao;HUO Bing-jie(Department of Traditional Chinese Medicine,Hebei Chest Hospital,Shijiazhuang 050010,China;不详)

机构地区：[1]河北省胸科医院中医科,石家庄050010 [2]河北医科大学第四医院中医科

出　　处：《医学动物防制》2023年第2期136-140,共5页Journal of Medical Pest Control

基　　金：河北省中医药管理局(2018088)。

摘　　要：目的 观察常规抗结核药物联合消瘰散结散口服加超声波导入,对浸润型浅表淋巴结核临床疗效及对机体免疫和炎症因子水平的影响。方法 选择2020年1月至2020年4月在河北省胸科医院住院的80例浸润型浅表淋巴结核患者,随机分为对照组与观察组。对照组为常规抗结核药物,观察组为对照组基础上加消瘰散结散口服和超声波导入治疗。治疗2个月观察2组临床有效率、中医证候总积分、免疫水平(CD3+、CD4+、CD8+、CD4+/CD8+)、炎症因子水平(IL-10、TNF-α)、随访情况和不良反应。结果 观察组总有效率(97.5%)高于对照组(82.5%),差异有统计学意义(χ^(2)=5.00,P<0.05)。2组治疗后,观察组中医证候总积分改善优于对照组,差异有统计学意义(t=-5.38,P<0.05)。观察组免疫水平改善均优于对照组,差异有统计学意义(t=5.44,P<0.05;t=10.56,P<0.05;t=-6.23,P<0.05;t=2.88,P<0.05)。治疗后观察组IL-10和TNF-α下降均优于对照组,差异有统计学意义(t=-2.07,P<0.05;t=-16.20,P<0.05)。随访显示观察组全部治愈优于对照组80.0%的治愈率,差异有统计学意义(χ^(2)=8.89,P<0.05)。不良反应差异无统计学意义(χ^(2)=0.21,P>0.05)。结论 常规抗结核药物联合消瘰散结散口服加超声波导入,可提高浸润型浅表淋巴结核临床疗效,改善中医证候,提高免疫水平,降低炎症因子水平,提高疗程后治愈率且未增加不良反应发生率。Objective To observe the clinical efficacy of conventional anti-tuberculosis drugs combined with oral administration of Xiaoluo Sanjie San and ultrasound on infiltrating superficial lymphatic tuberculosis and its effect on the body′s immune level and inflammatory factor levels.Methods Eighty cases of infiltrating superficial lymphatic tuberculosis who were admitted in Hebei Chest Hospital from January 2020 to April 2020 were randomly divided into a control group and an observation group.The control group was treated with conventional anti-tuberculosis drugs, and the observation group was treated with Xiaoluo Sanjie San orally and ultrasound guided in addition to the control group.After 2 months of treatment, the clinical effective rate, total score of TCM syndromes, immune level(CD3+,CD4+,CD8+,CD4+/CD8+),inflammatory factor levels(IL-10,TNF-α),follow-up status and adverse reactions were observed in the two groups.Results The total effective rate of the observation group(97.5%) was higher than that of the control group(82.5%),and the difference was statistically significant(χ^(2)=5.00,P<0.05).After treatment in the two groups, the total score of TCM syndromes in the observation group improved better than that in the control group, and the difference was statistically significant(t=-5.38,P<0.05).The immune level of the observation group was improved better than that of the control group, and the difference was statistically significant(t=5.44,P<0.05;t=10.56,P<0.05;t=-6.23,P<0.05;t=2.88,P<0.05).The decrease in IL-10 and TNF-α after treatment was better than the control group, which was statistically significant(t=-2.07,P<0.05;t=-16.20,P<0.05).Follow-up showed that the observation group was better than the control group with 80.0% cure rate, and the difference was statistically significant(χ^(2)=8.89,P<0.05).There was no significant difference in adverse reactions(χ^(2)=0.21,P>0.05).Conclusion The oral administration of Xiaoluo Sanjie San combined with ultrasound introduction and combined with conventional ant

关 键 词：消瘰散结散 超声波导入 浅表淋巴结核 浸润型 免疫水平 炎症因子 

分 类 号：R521.2[医药卫生—内科学]